Longeveron Stock (NASDAQ:LGVN)
Previous Close
$1.49
52W Range
$0.77 - $6.40
50D Avg
$1.55
200D Avg
$2.02
Market Cap
$21.61M
Avg Vol (3M)
$264.57K
Beta
0.38
Div Yield
-
LGVN Company Profile
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.
LGVN Performance
Peer Comparison
| Ticker | Company |
|---|---|
| KZR | Kezar Life Sciences, Inc. |
| CCCC | C4 Therapeutics, Inc. |
| ABVC | ABVC BioPharma, Inc. |
| KRON | Kronos Bio, Inc. |
| SRZN | Surrozen, Inc. |
| BOLT | Bolt Biotherapeutics, Inc. |
| NTRB | Nutriband Inc. |
| KPRX | Kiora Pharmaceuticals, Inc. |
| KROS | Keros Therapeutics, Inc. |
| ERAS | Erasca, Inc. |
| VRAX | Virax Biolabs Group Limited |
| LRMR | Larimar Therapeutics, Inc. |
| REVB | Revelation Biosciences, Inc. |
| EWTX | Edgewise Therapeutics, Inc. |
| QNRX | Quoin Pharmaceuticals, Ltd. |
| KTTA | Pasithea Therapeutics Corp. |
| INDP | Indaptus Therapeutics, Inc. |
| RNXT | RenovoRx, Inc. |
| GBIO | Generation Bio Co. |
| FBRX | Forte Biosciences, Inc. |